


PHARMACEUTICAL 2021

Kronos Bio Inc. Rank 88 of 409





PHARMACEUTICAL 2021



Kronos Bio Inc. Rank 88 of 409

The relative strengths and weaknesses of Kronos Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kronos Bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 129% points. The greatest weakness of Kronos Bio Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 55%, being 410% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	419,802
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,856
Liabilities, Non-Current	33,589
Other Assets	92,162
Other Compr. Net Income	-1.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-30,400
Property and Equipment	0
Research and Development	43,250
Revenues	0
Selling, General and Administrative Expense	14,794

Output Variable	Value in 1000 USD
Assets	511,964
Liabilities	46,445
Expenses	58,044
Stockholders Equity	465,519
Net Income	-88,444
Comprehensive Net Income	-88,444
Economic Capital Ratio	55%